Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882

Watchlist Manager
Guangzhou Kingmed Diagnostics Group Co Ltd Logo
Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882
Watchlist
Price: 28.99 CNY -1.6% Market Closed
Market Cap: 13.4B CNY
Have any thoughts about
Guangzhou Kingmed Diagnostics Group Co Ltd?
Write Note

Guangzhou Kingmed Diagnostics Group Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Guangzhou Kingmed Diagnostics Group Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882
Total Equity
ÂĄ7.8B
CAGR 3-Years
12%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Jinxin Fertility Group Ltd
HKEX:1951
Total Equity
ÂĄ10.1B
CAGR 3-Years
11%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Topchoice Medical Co Inc
SSE:600763
Total Equity
ÂĄ3.9B
CAGR 3-Years
12%
CAGR 5-Years
18%
CAGR 10-Years
20%
Nanjing Xinjiekou Department Store Co Ltd
SSE:600682
Total Equity
ÂĄ17.5B
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
28%
Dian Diagnostics Group Co Ltd
SZSE:300244
Total Equity
ÂĄ7.4B
CAGR 3-Years
8%
CAGR 5-Years
13%
CAGR 10-Years
28%
Meinian Onehealth Healthcare Holdings Co Ltd
SZSE:002044
Total Equity
ÂĄ7.4B
CAGR 3-Years
-1%
CAGR 5-Years
3%
CAGR 10-Years
35%
No Stocks Found

Guangzhou Kingmed Diagnostics Group Co Ltd
Glance View

Market Cap
13.6B CNY
Industry
Health Care

Guangzhou Kingmed Diagnostics Group Co Ltd has crafted its journey in the healthcare industry with precision and analytical prowess. Emerging in the early 2000s, Kingmed Diagnostics tapped into a burgeoning market niche—offering diagnostic testing services to hospitals, clinics, and other medical institutions. With a blend of advanced technology and extensive scientific expertise, the company provides a range of services, from routine clinical testing to esoteric evaluations that require more sophisticated techniques. Kingmed’s laboratories, strategically established across China, facilitate a seamless operation that processes millions of tests annually, ensuring timely and accurate results. This operational efficiency not only supports healthcare providers in delivering informed patient care but also positions Kingmed at the forefront of diagnostic innovation. Revenue streams flow through service contracts with healthcare facilities and direct partnerships where they provide specialized testing offerings that institutions may not have the infrastructure to perform in-house. By leveraging economies of scale, Kingmed achieves cost efficiencies, which in turn afford competitive pricing structures, further securing its market position. Complementing its robust diagnostic services, the company also invests in research and development initiatives, continuously enhancing its test portfolio. This commitment to innovation ensures that they stay relevant in the ever-evolving healthcare landscape, capturing new opportunities and expanding their market reach. Through this strategic framework, Guangzhou Kingmed Diagnostics not only sustains its financial growth but also fortifies its leadership in the diagnostic services sector.

Intrinsic Value
46.73 CNY
Undervaluation 38%
Intrinsic Value
Price

See Also

What is Guangzhou Kingmed Diagnostics Group Co Ltd's Total Equity?
Total Equity
7.8B CNY

Based on the financial report for Sep 30, 2024, Guangzhou Kingmed Diagnostics Group Co Ltd's Total Equity amounts to 7.8B CNY.

What is Guangzhou Kingmed Diagnostics Group Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
29%

Over the last year, the Total Equity growth was -7%. The average annual Total Equity growth rates for Guangzhou Kingmed Diagnostics Group Co Ltd have been 12% over the past three years , 29% over the past five years .

Back to Top